OrbiMed Israel GP Ltd. - May 11, 2021 Form 4 Insider Report for 9 METERS BIOPHARMA, INC. (NMTR)

Role
10%+ Owner
Signature
/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Israel GP Ltd.
Stock symbol
NMTR
Transactions as of
May 11, 2021
Transactions value $
$20,836
Form type
4
Date filed
5/13/2021, 06:34 PM
Next filing
Jun 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NMTR Common Stock Exercise of in-the-money or at-the-money derivative security $8.75K +12.5K +0.05% $0.70 25.7M May 11, 2021 See Footnotes F1, F2
transaction NMTR Common Stock Exercise of in-the-money or at-the-money derivative security $12.1K +19.4K +0.08% $0.62 25.7M May 11, 2021 See Footnotes (1)(2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMTR Stock Option (right to buy) Exercise of in-the-money or at-the-money derivative security $0 +12.5K +50% $0.00 37.5K May 11, 2021 Common Stock 12.5K $0.70 See Footnotes F2, F3
transaction NMTR Stock Option (right to buy) Exercise of in-the-money or at-the-money derivative security $0 +19.4K +31.82% $0.00 80.6K May 11, 2021 Common Stock 19.4K $0.62 See Footnotes F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OrbiMed Israel Partners Limited Partnership ("OIP"), and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
F2 This report is being jointly filed by OrbiMed BioFund. and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 This option was granted to Darvish on April 30, 2020 and vests in 36 monthly installments beginning April 30, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
F4 This option was granted to Darvish on July 6, 2020 and vests in 36 monthly installments beginning July 6, 2020. Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.